Search Results - "Gitelman, Stephen E."

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? by Ferrara, Christine Therese, Geyer, Susan Michelle, Liu, Yuk-Fun, Evans-Molina, Carmella, Libman, Ingrid M, Besser, Rachel, Becker, Dorothy J, Rodriguez, Henry, Moran, Antoinette, Gitelman, Stephen E, Redondo, Maria J

“…We aimed to determine the effect of elevated BMI over time on the progression to type 1 diabetes in youth. We studied 1,117 children in the TrialNet Pathway to…”
Get full text

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial by Orban, Tihamer, MD, Bundy, Brian, PhD, Becker, Dorothy J, Prof, DiMeglio, Linda A, MD, Gitelman, Stephen E, Prof, Goland, Robin, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Marks, Jennifer B, Prof, Monzavi, Roshanak, MD, Moran, Antoinette, Prof, Raskin, Philip, Prof, Rodriguez, Henry, Prof, Russell, William E, Prof, Schatz, Desmond, Prof, Wherrett, Diane, MD, Wilson, Darrell M, Prof, Krischer, Jeffrey P, Prof, Skyler, Jay S, Dr, Prof

“…Summary Background The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a…”
Get full text

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial by Wherrett, Diane K, MD, Bundy, Brian, PhD, Becker, Dorothy J, Prof, DiMeglio, Linda A, MD, Gitelman, Stephen E, Prof, Goland, Robin, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Herold, Kevan C, Prof, Marks, Jennifer B, Prof, Monzavi, Roshanak, MD, Moran, Antoinette, Prof, Orban, Tihamer, MD, Palmer, Jerry P, MD, Raskin, Philip, Prof, Rodriguez, Henry, Prof, Schatz, Desmond, Prof, Wilson, Darrell M, Prof, Krischer, Jeffrey P, Prof, Skyler, Jay S, Dr, Prof

“…Summary Background Glutamic acid decarboxylase (GAD) is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. In animal models of…”
Get full text

A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes by HEROLD, Kevan C, GITELMAN, Stephen E, MASHARANI, Umesh, HAGOPIAN, William, BISIKIRSKA, Brygida, DONALDSON, David, ROTHER, Kristina, DIAMOND, Beverly, HARLAN, David M, BLUESTONE, Jeffrey A

“…A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years…”
Get full text

The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes by Dong, Shen, Hiam-Galvez, Kamir J, Mowery, Cody T, Herold, Kevan C, Gitelman, Stephen E, Esensten, Jonathan H, Liu, Weihong, Lares, Angela P, Leinbach, Ashley S, Lee, Michael, Nguyen, Vinh, Tamaki, Stanley J, Tamaki, Whitney, Tamaki, Courtney M, Mehdizadeh, Morvarid, Putnam, Amy L, Spitzer, Matthew H, Ye, Chun Jimmie, Tang, Qizhi, Bluestone, Jeffrey A

“…BACKGROUNDA previous phase I study showed that the infusion of autologous Tregs expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an…”
Get full text

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial by Rigby, Mark R, Prof, DiMeglio, Linda A, Prof, Rendell, Marc S, MD, Felner, Eric I, Prof, Dostou, Jean M, Prof, Gitelman, Stephen E, Prof, Patel, Chetanbabu M, MD, Griffin, Kurt J, Prof, Tsalikian, Eva, Prof, Gottlieb, Peter A, Prof, Greenbaum, Carla J, MD, Sherry, Nicole A, MD, Moore, Wayne V, MD, Monzavi, Roshanak, MD, Willi, Steven M, MD, Raskin, Philip, Prof, Moran, Antoinette, Prof, Russell, William E, Prof, Pinckney, Ashley, MS, Keyes-Elstein, Lynette, DrPH, Howell, Michael, PhD, Aggarwal, Sudeepta, PhD, Lim, Noha, PhD, Phippard, Deborah, PhD, Nepom, Gerald T, MD, McNamara, James, MD, Ehlers, Mario R, MBChB

“…Summary Background Type 1 diabetes results from autoimmune targeting of the pancreatic β cells, likely mediated by effector memory T (Tem) cells. CD2, a T cell…”
Get full text

Relation of body fat indexes to vitamin D status and deficiency among obese adolescents by Lenders, Carine M, Feldman, Henry A, Von Scheven, Emily, Merewood, Anne, Sweeney, Carol, Wilson, Darrell M, Lee, Phillip DK, Abrams, Stephanie H, Gitelman, Stephen E, Wertz, Marcia S, Klish, William J, Taylor, George A, Chen, Tai C, Holick, Michael F

“…BACKGROUND: Data on the relation between vitamin D status and body fat indexes in adolescence are lacking. OBJECTIVE: The objective was to identify factors…”
Get full text

Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy by Amon, Ron, Ben-Arye, Shani Leviatan, Engler, Limor, Yu, Hai, Lim, Noha, Berre, Ludmilla Le, Harris, Kristina M, Ehlers, Mario R, Gitelman, Stephen E, Chen, Xi, Soulillou, Jean-Paul, Padler-Karavani, Vered

“…Humans have circulating antibodies against diverse glycans containing -glycolylneuraminic acid (Neu5Gc) due to function-loss mutation of the gene. This…”
Get full text

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial by Gitelman, Stephen E, Prof, Gottlieb, Peter A, Prof, Rigby, Mark R, Prof, Felner, Eric I, Prof, Willi, Steven M, MD, Fisher, Lynda K, MD, Moran, Antoinette, Prof, Gottschalk, Michael, Prof, Moore, Wayne V, MD, Pinckney, Ashley, MS, Keyes-Elstein, Lynette, PhD, Aggarwal, Sudeepta, PhD, Phippard, Deborah, PhD, Sayre, Peter H, Prof, Ding, Linna, PhD, Bluestone, Jeffrey A, Prof, Ehlers, Mario R, MBChB

“…Summary Background Type 1 diabetes results from T-cell-mediated destruction of β cells. Findings from preclinical studies and pilot clinical trials suggest…”
Get full text

Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments by Rochdi, Moulay D, Vargas, Gabriel A, Carpentier, Eric, Oligny-Longpré, Geneviève, Chen, Stanford, Kovoor, Abraham, Gitelman, Stephen E, Rosenthal, Stephen M, von Zastrow, Mark, Bouvier, Michel

“…Substitution of arginine-137 of the vasopressin type 2 receptor (V2R) for histidine (R137H-V2R) leads to nephrogenic diabetes insipidus (NDI), whereas…”
Get more information

Two-Center Randomized Controlled Feasibility Trial of Insulin Pump Therapy in Young Children With Diabetes by Wilson, Darrell M, Buckingham, Bruce A, Kunselman, Elizabeth L, Sullivan, Mary M, Paguntalan, Helen U, Gitelman, Stephen E

“…OBJECTIVE:--Our goals were to determine if continuous subcutaneous insulin infusion (CSII), compared with those continuing multiple daily injections (MDIs),…”
Get full text

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes by Herold, Kevan C, Bundy, Brian N, Long, S. Alice, Bluestone, Jeffrey A, DiMeglio, Linda A, Dufort, Matthew J, Gitelman, Stephen E, Gottlieb, Peter A, Krischer, Jeffrey P, Linsley, Peter S, Marks, Jennifer B, Moore, Wayne, Moran, Antoinette, Rodriguez, Henry, Russell, William E, Schatz, Desmond, Skyler, Jay S, Tsalikian, Eva, Wherrett, Diane K, Ziegler, Anette-Gabriele, Greenbaum, Carla J

“…In this trial, high-risk nondiabetic relatives of patients with type 1 diabetes were randomly assigned to receive teplizumab (an anti-CD3 monoclonal antibody)…”
Get full text

β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes by Gitelman, Stephen E, Evans-Molina, Carmella, Guolo, Annamaria, Mari, Andrea, Ferrannini, Ele

“…Following a diagnosis of type 1 diabetes (T1D), persisting C-peptide secretion leads to improved glycemic control and outcomes. Residual β-cell function is…”
Get full text

Type 1 diabetes immunotherapy using polyclonal regulatory T cells by Bluestone, Jeffrey A, Buckner, Jane H, Fitch, Mark, Gitelman, Stephen E, Gupta, Shipra, Hellerstein, Marc K, Herold, Kevan C, Lares, Angela, Lee, Michael R, Li, Kelvin, Liu, Weihong, Long, S Alice, Masiello, Lisa M, Nguyen, Vinh, Putnam, Amy L, Rieck, Mary, Sayre, Peter H, Tang, Qizhi

“…Type 1 diabetes (T1D) is an autoimmune disease that occurs in genetically susceptible individuals. Regulatory T cells (Tregs) have been shown to be defective…”
Get more information

Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes by Ramos, Eleanor L, Dayan, Colin M, Chatenoud, Lucienne, Sumnik, Zdenek, Simmons, Kimber M, Szypowska, Agnieszka, Gitelman, Stephen E, Knecht, Laura A, Niemoeller, Elisabeth, Tian, Wei, Herold, Kevan C

“…Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes…”
Get full text

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes by Battaglia, Manuela, Ahmed, Simi, Anderson, Mark S, Atkinson, Mark A, Becker, Dorothy, Bingley, Polly J, Bosi, Emanuele, Brusko, Todd M, DiMeglio, Linda A, Evans-Molina, Carmella, Gitelman, Stephen E, Greenbaum, Carla J, Gottlieb, Peter A, Herold, Kevan C, Hessner, Martin J, Knip, Mikael, Jacobsen, Laura, Krischer, Jeffrey P, Long, S Alice, Lundgren, Markus, McKinney, Eoin F, Morgan, Noel G, Oram, Richard A, Pastinen, Tomi, Peters, Michael C, Petrelli, Alessandra, Qian, Xiaoning, Redondo, Maria J, Roep, Bart O, Schatz, Desmond, Skibinski, David, Peakman, Mark

“…The clinical diagnosis of new-onset type 1 diabetes has, for many years, been considered relatively straightforward. Recently, however, there is increasing…”
Get full text

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function by Herold, Kevan C, Gitelman, Stephen E, Gottlieb, Peter A, Knecht, Laura A, Raymond, Ralph, Ramos, Eleanor L

“…In November 2022, teplizumab-mzwv became the first drug approved to delay the onset of stage 3 type 1 diabetes in adults and children age ≥8 years with stage 2…”
Get full text

Regulatory T cell therapy for type 1 diabetes: May the force be with you by Gitelman, Stephen E, Bluestone, Jeffrey A

“…Abstract Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of insulin producing beta cells. Regulatory T cells (Tregs) have been shown to be…”
Get full text

Real-Time Continuous Glucose Monitoring in Adolescents and Young Adults With Type 2 Diabetes Can Improve Quality of Life by Chesser, Hannah, Srinivasan, Shylaja, Puckett, Cassidy, Gitelman, Stephen E., Wong, Jenise C.

“…Objective: Real-time continuous glucose monitoring (CGM) is effective for diabetes management in cases of type 1 diabetes and adults with type 2 diabetes (T2D)…”
Get full text

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders by Herold, Kevan C., Gitelman, Stephen E., Ehlers, Mario R., Gottlieb, Peter A., Greenbaum, Carla J., Hagopian, William, Boyle, Karen D., Keyes-Elstein, Lynette, Aggarwal, Sudeepta, Phippard, Deborah, Sayre, Peter H., McNamara, James, Bluestone, Jeffrey A.

“…Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our…”
Get full text